Atavistik Bio Strengthens Leadership Team with Appointment of Paul Bruno, Ph.D. as Chief Business Officer Atavistik Bio, focused on discovering the next generation of precision allosteric therapeutics, announces the appointment of Paul Bruno, Ph.D. as CBO.

Atavistik Bio Raises Additional $40 Million to Advance Precision Allosteric Small Molecule Therapeutics Atavistik Bio announced that it has raised an additional $40 million to advance its precision allosteric small molecule therapeutic pipeline.

Atavistik Bio Appoints Bryan Stuart as Chief Executive Officer Mr. Stuart brings more than 25 years of biopharma executive leadership, corporate strategy, and business development experience to guide Atavistik Bio’s advancing discovery pipelineJeff Goater,...

Atavistik Bio Announces Publication in Science by Co-Founder Jared Rutter Describing Foundational Technology for its Atavistik Metabolite-Protein Screening (AMPS) Platform MIDAS (mass spectrometry integrated with equilibrium dialysis for the discovery of allostery systematically), in-licensed and industrialized by Atavistik Bio as the basis of AMPS, is the first...

Atavistik Bio Announces Collaboration with Plex Research to Enrich the Informatics Capabilities of its AMPS Platform and Accelerate the Discovery of Novel Small Molecule Therapeutics CAMBRIDGE, Mass., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Atavistik Bio, a biotechnology company focused on revolutionizing the discovery of new allosteric protein-metabolite interactions to develop novel...